Compare VRTX & COP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | VRTX | COP |
|---|---|---|
| Founded | 1989 | 1917 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Integrated oil Companies |
| Sector | Technology | Energy |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 115.7B | 136.5B |
| IPO Year | 2006 | 2005 |
| Metric | VRTX | COP |
|---|---|---|
| Price | $441.30 | $121.48 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 29 | 22 |
| Target Price | ★ $539.69 | $123.59 |
| AVG Volume (30 Days) | 1.2M | ★ 8.6M |
| Earning Date | 05-04-2026 | 04-30-2026 |
| Dividend Yield | N/A | ★ 2.83% |
| EPS Growth | ★ 836.54 | N/A |
| EPS | ★ 15.32 | 6.35 |
| Revenue | $2,488,652,000.00 | ★ $58,944,000,000.00 |
| Revenue This Year | $10.81 | $1.23 |
| Revenue Next Year | $10.41 | $2.12 |
| P/E Ratio | $28.88 | ★ $18.72 |
| Revenue Growth | ★ 46.20 | 7.67 |
| 52 Week Low | $362.50 | $84.28 |
| 52 Week High | $510.77 | $135.87 |
| Indicator | VRTX | COP |
|---|---|---|
| Relative Strength Index (RSI) | 44.66 | 46.08 |
| Support Level | $427.52 | $91.18 |
| Resistance Level | $442.22 | $122.50 |
| Average True Range (ATR) | 10.82 | 3.79 |
| MACD | 0.78 | -1.85 |
| Stochastic Oscillator | 55.61 | 21.57 |
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease, and Journavx, a non-opioid pain medication approved for the treatment of moderate-to-severe acute pain in adults. Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
ConocoPhillips is a US-based independent exploration and production firm. Its operations are primarily in Alaska and the Lower 48, with footprints in Canada, Europe, Asia-Pacific, the Middle East, and Africa. It also has substantial integrated LNG production and marketing activities across geographies.